Piroxicam reverses endotoxin-induced hypotension in rats: contribution of vasoactive eicosanoids and nitric oxide

C Kemal Buharalioglu1, Belma Korkmaz, Tuba Cuez

  • 1Department of Pharmacology, Faculty of Pharmacy, Mersin University, Turkey.

Insights

Piroxicam, a preferential COX-1 inhibitor, reversed endotoxin-induced hypotension in rats by increasing 20-HETE production and decreasing iNOS and COX-2 expression. This study highlights piroxicam

Area of Science:

  • Pharmacology
  • Physiology
  • Biochemistry

Background:

  • Endotoxemia causes hypotension and organ failure due to increased nitric oxide (NO) from inducible NO synthase (iNOS).
  • Endotoxic shock also involves decreased cyclooxygenase (COX-1), cytochrome P450 (CYP) 4A, and endothelial NOS (eNOS) expression.
  • Previous research indicated dual iNOS and COX inhibition restores blood pressure via increased 20-hydroxyeicosatetraenoic acid (20-HETE) in endotoxemic rats.

Purpose of the Study:

  • To investigate the effects of piroxicam, a preferential COX-1 inhibitor, on endotoxin-induced changes.
  • To analyze alterations in blood pressure, protein expression (COX-1, COX-2, CYP4A1, eNOS, iNOS, hsp90), and metabolite production (PGI(2), PGE(2), 20-HETE, NO).

Main Methods:

  • Male Wistar rats were injected with endotoxin (10 mg/kg, i.p.).
  • Piroxicam (10 mg/kg, i.p.) was administered 1 hour after endotoxin.
  • Measurements included blood pressure, heart rate, renal levels of 6-keto-PGF(1α), PGE(2), nitrite, and 20-HETE.
  • Protein expression of COX-1, COX-2, CYP4A1, eNOS, iNOS, and hsp90 was assessed.

Main Results:

  • Endotoxin caused hypotension, increased heart rate, elevated renal 6-keto-PGF(1α), PGE(2), and nitrite levels, with increased COX-2 and iNOS expression.
  • Systemic and renal 20-HETE levels, and renal eNOS, COX-1, and CYP4A1 expression were decreased by endotoxin.
  • Piroxicam administration prevented most endotoxin-induced effects, except for renal COX-1 and eNOS expression.

Conclusions:

  • Piroxicam effectively reversed endotoxin-induced hypotension in rats.
  • The protective effect of piroxicam is linked to reduced COX-2 and iNOS expression and increased CYP4A1 expression and 20-HETE synthesis.
  • These findings suggest a therapeutic potential for piroxicam in managing endotoxemia.

Related Concept Videos

Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...